GO
Loading...

Pfizer Inc

More

  • The Waiting Game Continues For Lilly & ImClone Monday, 29 Sep 2008 | 10:42 AM ET
    lilly_hq.jpg

    Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.

  • Lilly

    Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.

  • S&P Slammed Monday, 22 Sep 2008 | 5:56 PM ET
    graphic_word_ofthe_street.jpg

    The Dow tumbled on Monday as investors worried a $700 billion bailout for the financial sector may not resuscitate a slumping economy...

  • Lightning Round OT: Pfizer, Vale and More Friday, 19 Sep 2008 | 6:51 PM ET

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • merck_manual.jpg

    As the press release that came with the book says, "Compact enough to carry in a lab coat pocket, the paperback helps health care practitioners, particularly those who are newcomers to clinical diagnosis, understand and evaluate a wide range of symptoms."

  • Pfizer Is A Driver: "Complaining" Investor Read On! Thursday, 18 Sep 2008 | 4:40 PM ET
    pfizer_hq.jpg

    The stock posted its biggest percentage gain in nearly three years and its biggest dollar gain in more than two years, according to CNBC stock-stat maven Robert Hum.

  • Dow Plunges 500 points Monday, 15 Sep 2008 | 4:55 PM ET
    080915 Indices.jpg

    The Dow and S&P 500 fell over 4.5% today, while the Nasdaq composite dropped 3.6%, as concerns over the health of the financial sector intensified following the decision of Lehman Brothers to file for Chapter 11.

  • Pfizer: A Delay And A Deal? Tuesday, 9 Sep 2008 | 12:06 PM ET

    At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.

  • Cramer makes the call on viewers' favorite stocks.

  • Pharma Stocks

    John Sullivan, the Director of Research at Lerrink Swann, which specializes in healthcare stocks, says there is a potential trading opportunity in the sector related to F & F.

  • Celgene's Success Story Thursday, 4 Sep 2008 | 3:37 PM ET

    One of the biggest biotech success stories is among the companies featured in the afternoon sessions here at the BioCentury/Thomson Reuters investment conference.

  • Medivation's Presentation Thursday, 4 Sep 2008 | 10:18 AM ET
    Medivation

    A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer, Medivation had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at today's BioCentury/Thomson Reuters biotech investment conference in New York City.

  • Biotech Bonanza At Industry Conference Thursday, 4 Sep 2008 | 9:09 AM ET

    Today I will be attending and blogging from the 15th Annual Newsmakers in the Biotech Industry conference which is put on by BioCentury Publications and Thomson Reuters. Three dozen biotechs will be making presentations and then doing hour-long q and a's during breakout sessions.

  • Pfizer Finding Innovation At Medivation Wednesday, 3 Sep 2008 | 10:32 AM ET
    Lilly Effient

    In late July at a big scientific conference in Chicago, I reported on new, positive data on Medivation's experimental Alzheimer's drug Dimebon (dim-uh-bahn).

  • For Widely Used Drug, Question of Usefulness Lingers Tuesday, 2 Sep 2008 | 4:51 AM ET
    PFIZER.jpg

    When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug, the New Yor Times reported.

  • Financials Lead Stocks to a Higher Finish Wednesday, 27 Aug 2008 | 5:21 PM ET

    Stocks finished higher in feather-light trading Wednesday, boosted by a rise in financials and energy stocks, as well as a better-than-expected durable-goods report.

  • When It Rains Risk, It Pours Wednesday, 27 Aug 2008 | 12:01 PM ET
    woman_in_rain.jpg

    Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals and Cell Genesys, much lower. After the closing bell Tuesday, Bristol-Myers Squibb and Pfizer had an announcement to make...

  • Pfizer Vs. Johnson & Johnson Tuesday, 26 Aug 2008 | 6:28 PM ET

    Cramer shows you how to value each stock so you know which is the better pick.

  • Stanford to Limit Drug Maker Financing Tuesday, 26 Aug 2008 | 11:09 AM ET
    Green wedding

    Stanford University, concerned about the influence drug companies may have on medical education, is expected to announce Tuesday that it will severely restrict industry financing of doctors’ continuing education at its medical school, according to the New York Times.

  • AstraZeneca's Flu Campaign Season Begins Monday, 25 Aug 2008 | 12:35 PM ET
    Flu Vaccination Button

    Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.